IN2012DN02368A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02368A
IN2012DN02368A IN2368DEN2012A IN2012DN02368A IN 2012DN02368 A IN2012DN02368 A IN 2012DN02368A IN 2368DEN2012 A IN2368DEN2012 A IN 2368DEN2012A IN 2012DN02368 A IN2012DN02368 A IN 2012DN02368A
Authority
IN
India
Prior art keywords
langerin
present
peptides
isolated anti
antibody
Prior art date
Application number
Other languages
English (en)
Inventor
Jacques F Banchereau
Sandra Zurawski
Gerard Zurawski
Eynav Klechevsky
Sangkon Oh
Original Assignee
Baylor Res Insitute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Insitute filed Critical Baylor Res Insitute
Publication of IN2012DN02368A publication Critical patent/IN2012DN02368A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
IN2368DEN2012 2009-09-14 2010-09-14 IN2012DN02368A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24228309P 2009-09-14 2009-09-14
PCT/US2010/048800 WO2011032161A2 (en) 2009-09-14 2010-09-14 Vaccines directed to langerhans cells

Publications (1)

Publication Number Publication Date
IN2012DN02368A true IN2012DN02368A (enrdf_load_stackoverflow) 2015-08-21

Family

ID=43733140

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2368DEN2012 IN2012DN02368A (enrdf_load_stackoverflow) 2009-09-14 2010-09-14

Country Status (12)

Country Link
US (2) US20110081343A1 (enrdf_load_stackoverflow)
EP (1) EP2477655A4 (enrdf_load_stackoverflow)
JP (2) JP2013504599A (enrdf_load_stackoverflow)
CN (1) CN102711824A (enrdf_load_stackoverflow)
AR (1) AR078423A1 (enrdf_load_stackoverflow)
AU (1) AU2010291939B2 (enrdf_load_stackoverflow)
BR (1) BR112012005713A2 (enrdf_load_stackoverflow)
CA (1) CA2774140A1 (enrdf_load_stackoverflow)
IN (1) IN2012DN02368A (enrdf_load_stackoverflow)
MX (1) MX2012003058A (enrdf_load_stackoverflow)
TW (1) TWI483734B (enrdf_load_stackoverflow)
WO (1) WO2011032161A2 (enrdf_load_stackoverflow)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8961991B2 (en) 2009-03-10 2015-02-24 Baylor Research Institute Anti-CD40 targeted fusion proteins
DK2406289T3 (en) 2009-03-10 2017-05-01 Baylor Res Inst ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES
EP2406286B1 (en) 2009-03-10 2016-05-18 Baylor Research Institute Anti-cd40 antibodies and uses thereof
AU2010291939B2 (en) 2009-09-14 2012-11-15 Baylor Research Institute Vaccines directed to Langerhans cells
CN103153338A (zh) 2010-05-07 2013-06-12 贝勒研究院 树突细胞免疫受体（dcir）介导的人类cd8+t细胞的交叉敏化
WO2012129227A1 (en) * 2011-03-22 2012-09-27 Baylor Research Institute Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine
EP2688592A4 (en) * 2011-03-25 2015-07-22 Baylor Res Inst Compositions and methods for immunization against the hepatitis C virus
AR088428A1 (es) * 2011-08-25 2014-06-11 Baylor Res Inst Ensayo multiplexado basado en esferas autoensambladas para anticuerpos especificos de antigenos
US9574013B2 (en) 2012-12-07 2017-02-21 Vanderbilt University Antibodies against factor XII and uses thereof
JP6566941B2 (ja) 2013-06-28 2019-08-28 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 多発性硬化症のための樹状細胞ａｓｇｐｒ標的化免疫治療薬
CA2928908C (en) * 2013-11-01 2021-01-12 Pfizer Inc. Vectors for expression of prostate-associated antigens
CA2936833A1 (en) 2014-01-13 2015-07-16 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
WO2016129660A1 (ja) * 2015-02-12 2016-08-18 国立大学法人東北大学 がん細胞特異的抗ポドカリキシン抗体とその製造方法
WO2017120280A1 (en) * 2016-01-06 2017-07-13 Virginia Tech Intellectual Properties, Inc. Antigen targeting to porcine langerin
EP3988111A1 (en) 2016-04-01 2022-04-27 Innovative Cellular Therapeutics Holdings, Ltd. Use of chimeric antigen receptor modified cells to treat cancer
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
US11162945B2 (en) * 2016-04-11 2021-11-02 Board Of Regents, The University Of Texas System Methods and compositions for detecting single T cell receptor affinity and sequence
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
WO2019141731A1 (en) 2018-01-18 2019-07-25 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Langerin+ cell targeting
CA3184802A1 (en) 2020-05-26 2021-12-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
CN111850004B (zh) * 2020-07-27 2022-04-22 齐鲁工业大学 一种活性提高的纤维小体对接蛋白突变体36740及应用
MX2023005570A (es) 2020-11-12 2023-05-29 Inst Nat Sante Rech Med Anticuerpos conjugados o fusionados al dominio de union del receptor de la proteina de la espicula de sars-cov-2 y usos de los mismos con fines de vacunacion.
US20240131138A1 (en) 2020-12-23 2024-04-25 Institut National De La Santé Et De La Recherche Médicale (Inserm) Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
WO2022162177A1 (en) 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes
TWI815572B (zh) * 2021-09-27 2023-09-11 美商圖策智能科技有限公司 特定病毒的突變耐受表位的推估方法及系統
JP2024540505A (ja) 2021-11-17 2024-10-31 アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル ユニバーサルサルベコウイルスワクチン
CN117343178A (zh) * 2022-07-04 2024-01-05 王昭 一种结合人cd207的抗体、抗人cd207的嵌合抗原受体及其应用
KR20250080855A (ko) 2022-10-05 2025-06-05 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 니파바이러스 감염에 대한 dc 표적 백신
WO2025111382A2 (en) * 2023-11-21 2025-05-30 Board Of Regents, The University Of Texas System Anti-lamp5 antibodies, engineered immune cells expressing anti-lamp5 antibodies, and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685930B1 (en) * 1991-03-27 2004-02-03 Tanox, Inc. Methods and substances for recruiting therapeutic agents to solid tumors
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US7560534B2 (en) * 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
KR100643818B1 (ko) 2000-05-08 2006-11-10 셀덱스 쎄라퓨틱스, 인크. 수상세포에 대한 인간 모노클로날 항체
ES2259030T3 (es) 2000-05-19 2006-09-16 Scancell Limited Anticuerpos humanizados frente al receptor del factor de crecimiento epidermico.
EP1461073B1 (en) * 2001-11-30 2010-01-06 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Peptide agonists of prostate-specific antigen, and uses therefor
KR20050114224A (ko) * 2003-03-04 2005-12-05 알렉시온 파마슈티칼스, 인코포레이티드 항원 제공 세포의 내성을 유도함으로써 자가 면역 질환치료 방법
US7309491B2 (en) * 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
AU2004281634B2 (en) * 2003-09-03 2011-01-27 Dendritherapeutics, Inc. Multiplex vaccines
KR101368035B1 (ko) * 2005-04-08 2014-02-26 아르고스 쎄라퓨틱스 인코포레이티드 수지상 세포 조성물 및 방법
ES2536900T3 (es) * 2007-02-02 2015-05-29 Baylor Research Institute Antígenos multivariables en complejo con anticuerpo monoclonal humanizado de dirección
SG187482A1 (en) * 2007-11-07 2013-02-28 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
BRPI0915915A2 (pt) * 2008-07-16 2019-09-24 Baylor Res Institute vacinas para hiv com base na marcação de gag e nef maximizada para células dendríticas
DK2406289T3 (en) * 2009-03-10 2017-05-01 Baylor Res Inst ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES
AU2010291939B2 (en) 2009-09-14 2012-11-15 Baylor Research Institute Vaccines directed to Langerhans cells

Also Published As

Publication number Publication date
WO2011032161A3 (en) 2011-08-25
JP2015110582A (ja) 2015-06-18
WO2011032161A8 (en) 2011-07-07
US20110081343A1 (en) 2011-04-07
MX2012003058A (es) 2012-05-22
TWI483734B (zh) 2015-05-11
AU2010291939B2 (en) 2012-11-15
CA2774140A1 (en) 2011-03-17
BR112012005713A2 (pt) 2019-09-24
US9315580B2 (en) 2016-04-19
EP2477655A4 (en) 2014-02-12
AU2010291939A1 (en) 2012-04-05
TW201116295A (en) 2011-05-16
JP2013504599A (ja) 2013-02-07
EP2477655A2 (en) 2012-07-25
CN102711824A (zh) 2012-10-03
AR078423A1 (es) 2011-11-09
WO2011032161A2 (en) 2011-03-17
US20140030264A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
IN2012DN02368A (enrdf_load_stackoverflow)
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
PH12017500890A1 (en) Antibody drug conjugates
TN2015000247A1 (en) Bcma antigen binding proteins
TN2014000120A1 (en) Cd27l antigen binding proteins
TW201613962A (en) Fabs-in-tandem immunoglobulin and uses thereof
EA201100268A1 (ru) Вакцина
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
WO2012027365A3 (en) Targeted multi-epitope dosage forms for induction of an immune response to antigens
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
EA030777B9 (ru) Анти-альфа-синуклеинсвязывающие молекулы
BR112016029579A2 (pt) anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
NZ718280A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
WO2012088247A3 (en) Anti-c5/c5a/c5adesr antibodies and fragments
EP3705494A3 (en) Antibodies against frizzled proteins and methods of use thereof
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2023000204A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
MX2014000531A (es) Metodos y composiciones para el tratamiento del asma usando anticuerpos anti-il-13.
WO2014131019A3 (en) Her-1, her-3 and igf-1r compositions and uses thereof
HK1218860A1 (zh) 卵巢癌疫苗及接种方法
EA201990218A1 (ru) Антитела с низкой иммуногенностью и их применения
MX2009003300A (es) Vectores de rhinovirus recombinantes.
MX2022005718A (es) Anticuerpos tmem219 y usos terapeuticos de los mismos.
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.